Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine

Yang, Chengbin; Chan, Kok Ken; Lin, Wen–Jen; Soehartono, Alana Mauluidy; Lin, Guimiao; Toh, Huiting; Yoon, Ho Sup; Chen, Chih‐Kuang; Yong, Ken‐Tye

doi:10.1007/s12274-017-1521-7

Cited by 52 publications

(51 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the BCPV without PEGylation (Figure S2a, Supporting Information) induced noticeable cytotoxicity when the concentration of BCPV exceeds 512 µg mL −1 (Figure S2b, Supporting Information). In our previous reports, it was also observed that BCPV induced low to moderate cytotoxicity on K562 (leukemia cell line) and MiaPaC‐2 cell lines (pancreatic cancer cell line). These results clearly supported our thought that PEGylation of BCPV can result in decreased toxicity.…”

Section: Resultsmentioning

confidence: 79%

“…To further investigate the synergistic anticancer activity of PEG‐BCPV/miR26a/miR122, the clonogenicity of HepG2 cells treated with PEG‐BCPV/miR26a/miR122 was studied by a cell colony formation assay( Figure a), which refers to the previous reports along with minor modification . Due to the excellent mimicking conditions for in vivo tumor cell growth, the cell colony assay has been widely used to assess the anticancer effect of various types of cancer therapies.…”

Section: Resultsmentioning

confidence: 99%

“…The distance of migration from the cellular monolayer to the wounded area during this time period was measured by NIS Elements Br Analysis 4.0 software. The invasive capacity of HepG2 cells treated with different formulations was verified by using 8.0 µm BD BioCoat Matrigel invasion chambers Assay System (BD Biosciences) according to the manufacturer's protocol . Briefly, HepG2 cells were transfected with PEG‐BCPV/miRNA for 48 h as described above.…”

Section: Methodsmentioning

confidence: 99%

“…The cancer treatment is relying on the simultaneous targeting of multiple oncogenes due to the complexity and heterogeneity of cancer . Thus, the novel therapeutic strategy has shifted from “one drug to one specified gene” paradigm to “one drug to multiple targeted genes” paradigm (like miRNA replacement therapy and chemogene synergistic therapy) . The mechanism of miRNA gene‐silencing lies in the miRNA–mRNA interaction, in which an incomplete complementarity binding occurs between the 3′‐untranslated region (3′‐UTR) sites of mRNA and the seed sequence of miRNA located at the positions 2–7 of its 5′‐end.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma

Yang

Yin

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Therapeutic strategy based on the restoration of tumor suppressor‐microRNAs (miRNAs) is a promising approach for cancer therapy, but the low delivery efficiency of miRNA remains a huge hurdle due to the lack of safe and efficient nonviral carriers. In this work, with the use of newly developed PEGylated biodegradable charged polyester‐based vectors (PEG‐BCPVs) as the carrier, the miR26a and miR122 codelivering therapeutic strategy (PEG‐BCPVs/miR26a/miR122 as the delivery formulation) is successfully developed for efficient treatment of human hepatocellular carcinoma (HCC). In vitro study results show that PEG‐BCPVs are capable of effectively facilitating miRNA cellular uptake via a cell endocytosis pathway. Consequently, the restoration of miR26a and miR122 remarkably inhibit the cell growth, migration, invasion, colony formation, and induced apoptosis of HepG2 cells. More importantly, the chemosensitivity of HepG2 to anticancer drug is also considerably enhanced. After treatment with the PEG‐BCPV‐based miRNA delivery system, the expression of the multiple targeted genes corresponding to miR26a and miR122 in HepG2 cells is greatly downregulated. Accordingly, the newly developed miRNA restoration therapeutic strategy via biodegradable PEG‐BCPVs as the carrier should be a promising modality for combating HCC.

show abstract

Section: Resultsmentioning

confidence: 79%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma

Yang

Yin

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…Before that, it is crucial to assess the biocompatibility and cytotoxicity of the NHCHCs. Hence, the cytotoxicity of NHCNC nanoparticles was evaluated by MTT assay using Hela cell (human cervical cancer cell line) 32 . As shown in Supplementary Fig.…”

Section: Discussionmentioning

confidence: 99%

Biocompatible Mesoporous Hollow Carbon Nanocapsules for High Performance Supercapacitors

Wang

Liu

Bradley

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

A facile and general method for the controllable synthesis of n-doped hollow mesoporous carbon nanocapsules (NHCNCs) with four different geometries has been developed. The spheres (NHCNC-1), low-concaves (NHCNC-2), semi-concaves (NHCNC-3) and wrinkles (NHCNC-4) shaped samples were prepared and systematically investigated to understand the structural effects of hollow particles on their supercapacitor performances. Compared with the other three different shaped samples (NHCNC-1, NHCNC-2, and NHCNC-4), the as-synthesized semi-concave structured NHCNC-3 demonstrated excellent performance with high gravimetric capacitance of 326 F g −1 (419 F cm −3 ) and ultra-stable cycling stability (96.6% after 5000 cycles). The outstanding performances achieved are attributed to the unique semi-concave structure, high specific surface area (1400 m 2 g −1 ), hierarchical porosity, high packing density (1.41 g cm −3 ) and high nitrogen (N) content (up to 3.73%) of the new materials. These carbon nanocapsules with tailorable structures and properties enable them as outstanding carriers and platforms for various emerging applications, such as nanoscale chemical reactors, catalysis, batteries, solar energy harvest, gas storage and so on. In addition, these novel carbons have negligible cytotoxicity and high biocompatibility for human cells, promising a wide range of bio applications, such as biomaterials, drug delivery, biomedicine, biotherapy and bioelectronic devices.Supercapacitors have drawn increasing attention due to their high power density, fast charge/discharge capability, long cycle life, low cost and environmental friendliness among various electrochemical energy storage devices 1 . Carbon materials are the most promising supercapacitor electrode materials, due to their high specific surface area, high electrical conductivity, tailorable pore structures and excellent chemical stability 2 . The pore structures and the surface properties of carbon materials have significant effects on the electrode performances 3 . In order to increase the volumetric capacitance of the electrode materials 4,5 , it is vital to optimize the morphology and reduce the void volume of the hollow porous carbon materials.Hollow carbon nanocapsules (HCNCs) are an interesting class of carbon materials, due to their unique properties such as high surface-to-volume ratio, low densities, large void space and high electrical conductivity 6,7 . The hollow macropore cavities and interior space of the HCNCs can act as anion-buffering reservoirs to shorten the diffusion distance of electrolyte ions 8 , while the mesopores and micropores in the shell can promote ion transport, minimize diffusion pathways from the electrolyte to the micropores, and increase the specific surface area to maximize the electric double layer capacitance 9 . For high-rate performances, HCNCs are particularly interesting as they have ultrahigh specific surface area, large surface-to-volume ratio, large void space along with an appropriate interconnected pore channels to facilitate ion ...

show abstract

Biodegradable Carbon Dioxide‐Derived Non‐Viral Gene Vectors for Osteosarcoma Gene Therapy

Lin

Yang

et al. 2022

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Osteosarcoma often occurs in children and adolescents with high invasiveness and high mortality. Polo‐like kinase 1 (PLK1) overexpressed in most tumors promotes cancer cell proliferation and transformation. PLK1 is considered as a therapeutic target for osteosarcoma. RNA interference‐based therapies are employed to combat osteosarcoma through silencing PLK1 gene expression. However, the treatment results remain unsatisfactory due to the lack of a safe and efficient nonviral gene vector. To tackle this hurdle, biodegradable and CO2‐derivative cationic poly(vinylcyclohexene carbonates) (CPCHCs) are used as gene vectors to perform a siPLK1 therapeutic strategy for osteosarcoma treatment. Of those CPCHCs, CPCHC60 demonstrates the most excellent performance in gene transfection efficiency, endo‐lysosome escaping, biodegradability, and biosafety. With the treatment of CPCHCs/siRNA nanoparticles, the expression level of PLK1 gene in osteosarcoma cells is significantly down‐regulated. Subsequently, cells are arrested in the G2/M phase and subsequently dead in the form of apoptosis, resulting in significant tumor regression both in vitro and in vivo. This study brings a new insight into the development of superior nonviral gene vectors for practical cancer treatment. Based on the results, the resulting nanoparticle‐based gene drug formation is considered to have a highly successful chance in further translational nanomedicine applications.

show abstract

Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine

Cited by 52 publications

References 53 publications

Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma

Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma

Biocompatible Mesoporous Hollow Carbon Nanocapsules for High Performance Supercapacitors

Biodegradable Carbon Dioxide‐Derived Non‐Viral Gene Vectors for Osteosarcoma Gene Therapy

Contact Info

Product

Resources

About